METTL1 promotes tumorigenesis through tRNA-derived fragment biogenesis in prostate cancer.

7-methylguanosine Epitranscriptome Immune checkpoint blockade Interferon Prostate cancer RNA modifications Tumour microenvironment (TME) tRNA fragments

Journal

Molecular cancer
ISSN: 1476-4598
Titre abrégé: Mol Cancer
Pays: England
ID NLM: 101147698

Informations de publication

Date de publication:
29 07 2023
Historique:
received: 03 08 2022
accepted: 17 06 2023
medline: 31 7 2023
pubmed: 30 7 2023
entrez: 29 7 2023
Statut: epublish

Résumé

Newly growing evidence highlights the essential role that epitranscriptomic marks play in the development of many cancers; however, little is known about the role and implications of altered epitranscriptome deposition in prostate cancer. Here, we show that the transfer RNA N

Identifiants

pubmed: 37516825
doi: 10.1186/s12943-023-01809-8
pii: 10.1186/s12943-023-01809-8
pmc: PMC10386714
doi:

Substances chimiques

METTL1 protein, human EC 2.1.1.-
Methyltransferases EC 2.1.1.-

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

119

Informations de copyright

© 2023. The Author(s).

Références

Nat Biotechnol. 2019 Jul;37(7):773-782
pubmed: 31061481
Curr Cancer Drug Targets. 2021;21(4):326-352
pubmed: 33504307
Cell. 2018 Jul 26;174(3):549-563.e19
pubmed: 29937226
Cell. 2015 May 21;161(5):1215-1228
pubmed: 26000489
EBioMedicine. 2017 Mar;17:5-6
pubmed: 28286059
J Immunother Cancer. 2020 Jul;8(2):
pubmed: 32616555
J Invest Dermatol. 2019 Nov;139(11):2302-2312.e14
pubmed: 31078570
Nat Rev Urol. 2018 Apr;15(4):222-234
pubmed: 29460925
J Mol Med (Berl). 2019 Nov;97(11):1535-1545
pubmed: 31463732
Int J Cancer. 2007 Oct 1;121(7):1579-84
pubmed: 17565746
Mol Cancer. 2021 Jan 18;20(1):18
pubmed: 33461542
Nat Commun. 2022 Mar 18;13(1):1478
pubmed: 35304469
Lancet. 2016 Jan 2;387(10013):70-82
pubmed: 26074382
Oncotarget. 2016 Apr 26;7(17):24766-77
pubmed: 27015120
Nucleic Acids Res. 2022 Jan 7;50(D1):D231-D235
pubmed: 34893873
J Med Genet. 2013 Jan;50(1):25-33
pubmed: 23160276
Nature. 2017 Jul 6;547(7661):109-113
pubmed: 28658205
Mol Cell. 2006 Jan 6;21(1):87-96
pubmed: 16387656
Clin Cancer Res. 2017 Sep 1;23(17):5187-5201
pubmed: 28698201
Nat Genet. 2007 Jan;39(1):41-51
pubmed: 17173048
Cancer Res. 2015 Jun 1;75(11):2139-45
pubmed: 25977340
Nat Commun. 2019 Jun 25;10(1):2782
pubmed: 31239444
Mol Ther. 2021 Dec 1;29(12):3422-3435
pubmed: 34371184
Nature. 2009 Sep 24;461(7263):495-500
pubmed: 19741607
Cell. 2010 Apr 2;141(1):39-51
pubmed: 20371344
Science. 2011 Jan 7;331(6013):44-9
pubmed: 21212348
EMBO J. 2014 Sep 17;33(18):2020-39
pubmed: 25063673
Neurol Sci. 2019 Feb;40(2):253-260
pubmed: 30361804
Mol Cell. 2021 Aug 19;81(16):3323-3338.e14
pubmed: 34352207
J Clin Invest. 2004 Mar;113(6):913-23
pubmed: 15067324
EMBO J. 2013 Oct 16;32(20):2751-63
pubmed: 24065129
Mol Cell. 2021 Aug 19;81(16):3339-3355.e8
pubmed: 34352206
FEBS Lett. 2010 Jan 21;584(2):265-71
pubmed: 19931536
Nat Med. 2021 Jul;27(7):1250-1261
pubmed: 34239134
Cancer Cell. 2010 Jul 13;18(1):11-22
pubmed: 20579941
Sci Rep. 2021 Jul 20;11(1):14784
pubmed: 34285249
Nature. 2018 Jun;558(7711):605-609
pubmed: 29925953
Cancer Discov. 2021 May;11(5):1248-1267
pubmed: 33323397
Mol Cell. 2010 Oct 22;40(2):228-37
pubmed: 20965418
Cell. 2018 Aug 23;174(5):1293-1308.e36
pubmed: 29961579
Nature. 2012 Feb 22;485(7396):55-61
pubmed: 22367541
Cancer Cell Int. 2021 Nov 27;21(1):633
pubmed: 34838021
N Engl J Med. 2012 Jun 28;366(26):2443-54
pubmed: 22658127
Genome Biol. 2011 Aug 18;12(8):R79
pubmed: 21851591
Signal Transduct Target Ther. 2021 Mar 26;6(1):127
pubmed: 33767177
CA Cancer J Clin. 2021 May;71(3):209-249
pubmed: 33538338
Cancer Res. 1977 Jan;37(1):285-92
pubmed: 187335
Nucleic Acids Res. 2018 Nov 2;46(19):10302-10318
pubmed: 30247717
RNA. 2008 Oct;14(10):2095-103
pubmed: 18719243
Oncogene. 2022 Apr;41(15):2239-2253
pubmed: 35217794
Annu Rev Genet. 2020 Nov 23;54:47-69
pubmed: 32841070
EMBO J. 2015 Sep 14;34(18):2350-62
pubmed: 26271101
Nucleic Acids Res. 2015 Apr 20;43(7):e47
pubmed: 25605792
Mol Cell. 2018 Jul 19;71(2):244-255.e5
pubmed: 29983320
J Hematol Oncol. 2020 Jun 22;13(1):81
pubmed: 32571374
Cancer Cell. 2021 Nov 8;39(11):1464-1478.e8
pubmed: 34719426
Nat Med. 2015 May;21(5):440-8
pubmed: 25849130
Nat Biotechnol. 2008 Dec;26(12):1367-72
pubmed: 19029910
Nat Commun. 2017 Oct 24;8(1):1127
pubmed: 29066746
Nat Methods. 2018 Mar;15(3):213-220
pubmed: 29431736
Nat Rev Mol Cell Biol. 2019 Oct;20(10):573-589
pubmed: 31270442
EMBO Mol Med. 2013 Mar;5(3):366-83
pubmed: 23381944
Nat Med. 2019 Jul;25(7):1073-1081
pubmed: 31270502
Nat Med. 2013 Oct;19(10):1264-72
pubmed: 24056773
PLoS Biol. 2019 Jun 14;17(6):e3000297
pubmed: 31199786
Nature. 2005 Aug 4;436(7051):725-30
pubmed: 16079851
Bioinformatics. 2010 Oct 1;26(19):2363-7
pubmed: 20688976
Br J Cancer. 2021 Jan;124(2):359-367
pubmed: 32929195
Proc Natl Acad Sci U S A. 2018 Mar 6;115(10):2353-2358
pubmed: 29467287
Trends Mol Med. 2014 Jun;20(6):306-14
pubmed: 24581449
Genes Dev. 2019 Jul 1;33(13-14):741-746
pubmed: 31171702
Mol Cell. 2011 Aug 19;43(4):613-23
pubmed: 21855800
Front Oncol. 2021 Feb 25;11:617289
pubmed: 33732644
Sci Rep. 2016 Dec 02;6:38243
pubmed: 27910903
Methods Enzymol. 2021;658:25-47
pubmed: 34517949
Proc Natl Acad Sci U S A. 2004 Jan 20;101(3):811-6
pubmed: 14711987
Nature. 2016 Jun 15;534(7607):335-40
pubmed: 27306184
J Neurol. 2019 Nov;266(11):2699-2709
pubmed: 31321514
Curr Mol Biol Rep. 2018;4(2):101-115
pubmed: 29888169
Cancer Discov. 2012 May;2(5):401-4
pubmed: 22588877
Nature. 2012 Jul 12;487(7406):239-43
pubmed: 22722839
PLoS Genet. 2014 Sep 18;10(9):e1004639
pubmed: 25233213
Genes Dev. 2010 Aug 1;24(15):1590-5
pubmed: 20679393
Nat Cell Biol. 2016 Jun;18(6):645-656
pubmed: 27214280
Angew Chem Int Ed Engl. 2018 Dec 17;57(51):16785-16790
pubmed: 30370969
Proc Natl Acad Sci U S A. 2014 Aug 12;111(32):11774-9
pubmed: 25071169
Cancer Cell. 2019 Aug 12;36(2):139-155.e10
pubmed: 31327655
Nat Cell Biol. 2019 May;21(5):552-559
pubmed: 31048770
Proc Natl Acad Sci U S A. 2005 Oct 25;102(43):15545-50
pubmed: 16199517
Nat Rev Cancer. 2020 Jun;20(6):303-322
pubmed: 32300195
Cell. 2010 Apr 2;141(1):129-41
pubmed: 20371350
Mol Cell. 2019 Jun 20;74(6):1278-1290.e9
pubmed: 31031083
Methods. 2020 Jun 1;178:49-62
pubmed: 31751605
EMBO Rep. 2020 Jun 4;21(6):e50162
pubmed: 32314873
Cell Rep. 2021 Dec 21;37(12):110132
pubmed: 34936871
Oncol Lett. 2021 Apr;21(4):330
pubmed: 33692862
Cancer Res. 2009 Oct 15;69(20):8127-32
pubmed: 19808971
Nat Cell Biol. 2019 Apr;21(4):511-521
pubmed: 30886344
J Clin Oncol. 2017 Jan;35(1):40-47
pubmed: 28034081
Cold Spring Harb Perspect Biol. 2019 Jul 1;11(7):
pubmed: 29959193
Nature. 2017 Mar 16;543(7645):428-432
pubmed: 28273064
Proc Natl Acad Sci U S A. 1996 Jul 23;93(15):7673-8
pubmed: 8755534
Cancer Cell. 2005 Nov;8(5):393-406
pubmed: 16286247
Cell. 2015 Aug 27;162(5):961-73
pubmed: 26317465
Methods Mol Biol. 2018;1711:243-259
pubmed: 29344893
Nat Chem Biol. 2013 May;9(5):319-25
pubmed: 23524983
Lancet Oncol. 2014 Jun;15(7):700-12
pubmed: 24831977
Nucleic Acids Res. 2022 Jul 8;50(12):6919-6937
pubmed: 35699207
Nat Genet. 2018 May;50(5):645-651
pubmed: 29610475
Endocr Relat Cancer. 2019 Jan 1;26(1):131-140
pubmed: 30400004
Nat Rev Immunol. 2014 Jan;14(1):36-49
pubmed: 24362405
EBioMedicine. 2015 Jul 29;2(9):1133-44
pubmed: 26501111
Cancer Res. 1991 Jan 1;51(1):190-4
pubmed: 1988083
Cell. 2015 Nov 5;163(4):1011-25
pubmed: 26544944
Mol Cell. 2019 Jun 20;74(6):1304-1316.e8
pubmed: 31031084
Science. 1996 May 3;272(5262):719-22
pubmed: 8614832
Nat Methods. 2009 May;6(5):359-62
pubmed: 19377485
Nature. 2023 Jan;613(7943):391-397
pubmed: 36599985
RNA Biol. 2020 Aug;17(8):1196-1213
pubmed: 32186461
Cell. 2018 Apr 5;173(2):291-304.e6
pubmed: 29625048
Genome Biol. 2016 Aug 22;17(1):174
pubmed: 27549193
Cancer Lett. 1980 Jun;9(4):339-43
pubmed: 7397688
Nat Commun. 2023 Feb 7;14(1):663
pubmed: 36750562
Cancer Cell. 2020 Jul 13;38(1):79-96.e11
pubmed: 32531268
Sci Signal. 2013 Apr 02;6(269):pl1
pubmed: 23550210
EMBO J. 2005 May 4;24(9):1696-705
pubmed: 15861136
Nat Cancer. 2021 Apr;2(4):444-456
pubmed: 33899001
Cell Rep. 2017 Oct 3;21(1):154-167
pubmed: 28978469
Cancer Res. 2023 Jan 4;83(1):89-102
pubmed: 36102722
RNA. 2002 Oct;8(10):1253-66
pubmed: 12403464
Cell. 2018 May 17;173(5):1204-1216.e26
pubmed: 29628141
J Exp Med. 2016 Oct 17;213(11):2503-2523
pubmed: 27811057
Gut. 2023 Aug;72(8):1555-1567
pubmed: 36283801
Br J Cancer. 2006 Jun 5;94(11):1726-33
pubmed: 16685264
Nat Methods. 2016 Sep;13(9):731-40
pubmed: 27348712
J Cell Biol. 2009 Apr 6;185(1):35-42
pubmed: 19332886
Proc Natl Acad Sci U S A. 2015 Jul 21;112(29):E3816-25
pubmed: 26124144
Nature. 2023 Jan;613(7943):383-390
pubmed: 36599982
Front Immunol. 2021 Aug 30;12:697026
pubmed: 34526985
Nucleic Acids Res. 2018 Jan 4;46(D1):D152-D159
pubmed: 29186503
Nat Cancer. 2021 Sep;2(9):932-949
pubmed: 35121864
J Hematol Oncol. 2020 Aug 3;13(1):107
pubmed: 32746880
Cell Rep. 2019 Aug 20;28(8):2156-2168.e5
pubmed: 31433989
Autophagy. 2023 Jan;19(1):360-362
pubmed: 35574843
Genes (Basel). 2021 Jan 10;12(1):
pubmed: 33435213
Cancer Res. 2018 Nov 1;78(21):6320-6328
pubmed: 30232219
Int J Cancer. 2019 Dec 1;145(11):3140-3151
pubmed: 31020993
Clin Transl Med. 2021 Dec;11(12):e675
pubmed: 34936728
Nat Rev Mol Cell Biol. 2021 Jun;22(6):375-392
pubmed: 33658722
Nature. 2018 Feb 1;554(7690):123-127
pubmed: 29364877
Science. 2015 Apr 3;348(6230):56-61
pubmed: 25838373
Nat Rev Immunol. 2019 Jun;19(6):369-382
pubmed: 30718830

Auteurs

Raquel García-Vílchez (R)

Centro de Investigación del Cáncer and Instituto de Biología Molecular y Celular del Cáncer, Consejo Superior de Investigaciones Científicas (CSIC)-University of Salamanca, 37007, Salamanca, Spain.
Instituto de Investigación Biomédica de Salamanca (IBSAL), Hospital Universitario de Salamanca, 37007, Salamanca, Spain.

Ana M Añazco-Guenkova (AM)

Centro de Investigación del Cáncer and Instituto de Biología Molecular y Celular del Cáncer, Consejo Superior de Investigaciones Científicas (CSIC)-University of Salamanca, 37007, Salamanca, Spain.
Instituto de Investigación Biomédica de Salamanca (IBSAL), Hospital Universitario de Salamanca, 37007, Salamanca, Spain.

Sabine Dietmann (S)

Washington University School of Medicine in St. Louis, 660S. Euclid Ave, St. Louis, MO, 63110, USA.

Judith López (J)

Centro de Investigación del Cáncer and Instituto de Biología Molecular y Celular del Cáncer, Consejo Superior de Investigaciones Científicas (CSIC)-University of Salamanca, 37007, Salamanca, Spain.
Instituto de Investigación Biomédica de Salamanca (IBSAL), Hospital Universitario de Salamanca, 37007, Salamanca, Spain.

Virginia Morón-Calvente (V)

Centro de Investigación del Cáncer and Instituto de Biología Molecular y Celular del Cáncer, Consejo Superior de Investigaciones Científicas (CSIC)-University of Salamanca, 37007, Salamanca, Spain.
Instituto de Investigación Biomédica de Salamanca (IBSAL), Hospital Universitario de Salamanca, 37007, Salamanca, Spain.

Silvia D'Ambrosi (S)

Present Address: Department of Neurosurgery, Cancer Center Amsterdam, Amsterdam UMC, Vrije Universiteit Amsterdam, 1081 HV, Amsterdam, The Netherlands.
CIC bioGUNE, Basque Research and Technology Alliance (BRTA), Bizkaia Technology Park, 801 Bld, 48160, Derio, Bizkaia, Spain.

Paz Nombela (P)

Centro de Investigación del Cáncer and Instituto de Biología Molecular y Celular del Cáncer, Consejo Superior de Investigaciones Científicas (CSIC)-University of Salamanca, 37007, Salamanca, Spain.
Instituto de Investigación Biomédica de Salamanca (IBSAL), Hospital Universitario de Salamanca, 37007, Salamanca, Spain.

Kepa Zamacola (K)

CIC bioGUNE, Basque Research and Technology Alliance (BRTA), Bizkaia Technology Park, 801 Bld, 48160, Derio, Bizkaia, Spain.

Isabel Mendizabal (I)

CIC bioGUNE, Basque Research and Technology Alliance (BRTA), Bizkaia Technology Park, 801 Bld, 48160, Derio, Bizkaia, Spain.
Ikerbasque, Basque Foundation for Science, 48011, Bilbao, Spain.

Saioa García-Longarte (S)

CIC bioGUNE, Basque Research and Technology Alliance (BRTA), Bizkaia Technology Park, 801 Bld, 48160, Derio, Bizkaia, Spain.

Amaia Zabala-Letona (A)

CIC bioGUNE, Basque Research and Technology Alliance (BRTA), Bizkaia Technology Park, 801 Bld, 48160, Derio, Bizkaia, Spain.
Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain.

Ianire Astobiza (I)

CIC bioGUNE, Basque Research and Technology Alliance (BRTA), Bizkaia Technology Park, 801 Bld, 48160, Derio, Bizkaia, Spain.
Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain.

Sonia Fernández (S)

CIC bioGUNE, Basque Research and Technology Alliance (BRTA), Bizkaia Technology Park, 801 Bld, 48160, Derio, Bizkaia, Spain.
Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain.

Alejandro Paniagua (A)

Centro de Investigación del Cáncer and Instituto de Biología Molecular y Celular del Cáncer, Consejo Superior de Investigaciones Científicas (CSIC)-University of Salamanca, 37007, Salamanca, Spain.

Borja Miguel-López (B)

Centro de Investigación del Cáncer and Instituto de Biología Molecular y Celular del Cáncer, Consejo Superior de Investigaciones Científicas (CSIC)-University of Salamanca, 37007, Salamanca, Spain.
Instituto de Investigación Biomédica de Salamanca (IBSAL), Hospital Universitario de Salamanca, 37007, Salamanca, Spain.

Virginie Marchand (V)

Université de Lorraine, UAR2008 IBSLor CNRS-UL-INSERM, Biopôle UL, 9, Avenue de La Forêt de Haye, 54505, Vandoeuvre-Les-Nancy, France.

Diego Alonso-López (D)

Bioinformatics Unit, Cancer Research Center (CIC-IBMCC, CSIC/USAL), Consejo Superior de Investigaciones Científicas (CSIC) and University of Salamanca (USAL), 37007, Salamanca, Spain.

Angelika Merkel (A)

Josep Carreras Leukaemia Research Institute (IJC), Badalona, 08916, Barcelona, Catalonia, Spain.
Germans Trias I Pujol Health Science Research Institute, Badalona, 08916, Barcelona, Catalonia, Spain.

Ignacio García-Tuñón (I)

Centro de Investigación del Cáncer and Instituto de Biología Molecular y Celular del Cáncer, Consejo Superior de Investigaciones Científicas (CSIC)-University of Salamanca, 37007, Salamanca, Spain.

Aitziber Ugalde-Olano (A)

Department of Pathology, Basurto University Hospital, 48013, Bilbao, Spain.

Ana Loizaga-Iriarte (A)

Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain.
Department of Urology, Basurto University Hospital, 48013, Bilbao, Spain.
Traslational Prostate Cancer Research Lab, CIC bioGUNE-Basurto, Biocruces Bizkaia Health Research Institute, Avenida Montevideo 18, 48013, Bilbao, Spain.

Isabel Lacasa-Viscasillas (I)

Department of Urology, Basurto University Hospital, 48013, Bilbao, Spain.

Miguel Unda (M)

Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain.
Department of Urology, Basurto University Hospital, 48013, Bilbao, Spain.
Traslational Prostate Cancer Research Lab, CIC bioGUNE-Basurto, Biocruces Bizkaia Health Research Institute, Avenida Montevideo 18, 48013, Bilbao, Spain.

Mikel Azkargorta (M)

CIC bioGUNE, Basque Research and Technology Alliance (BRTA), Bizkaia Technology Park, 801 Bld, 48160, Derio, Bizkaia, Spain.
Carlos III Networked Proteomics Platform (ProteoRed-ISCIII), Madrid, Spain.

Félix Elortza (F)

CIC bioGUNE, Basque Research and Technology Alliance (BRTA), Bizkaia Technology Park, 801 Bld, 48160, Derio, Bizkaia, Spain.
Carlos III Networked Proteomics Platform (ProteoRed-ISCIII), Madrid, Spain.
Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), Madrid, Spain.

Laura Bárcena (L)

CIC bioGUNE, Basque Research and Technology Alliance (BRTA), Bizkaia Technology Park, 801 Bld, 48160, Derio, Bizkaia, Spain.

Monika Gonzalez-Lopez (M)

CIC bioGUNE, Basque Research and Technology Alliance (BRTA), Bizkaia Technology Park, 801 Bld, 48160, Derio, Bizkaia, Spain.

Ana M Aransay (AM)

CIC bioGUNE, Basque Research and Technology Alliance (BRTA), Bizkaia Technology Park, 801 Bld, 48160, Derio, Bizkaia, Spain.
Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), Madrid, Spain.

Tomás Di Domenico (T)

Bioinformatics Unit, Spanish National Cancer Research Centre (CNIO), 28029, Madrid, Spain.

Manuel A Sánchez-Martín (MA)

Instituto de Investigación Biomédica de Salamanca (IBSAL), Hospital Universitario de Salamanca, 37007, Salamanca, Spain.
Servicio de Transgénesis, Nucleus, Universidad de Salamanca, 37007, Salamanca, Spain.

Javier De Las Rivas (J)

Centro de Investigación del Cáncer and Instituto de Biología Molecular y Celular del Cáncer, Consejo Superior de Investigaciones Científicas (CSIC)-University of Salamanca, 37007, Salamanca, Spain.

Sònia Guil (S)

Josep Carreras Leukaemia Research Institute (IJC), Badalona, 08916, Barcelona, Catalonia, Spain.
Germans Trias I Pujol Health Science Research Institute, Badalona, 08916, Barcelona, Catalonia, Spain.

Yuri Motorin (Y)

Université de Lorraine, UAR2008 IBSLor CNRS-UL-INSERM, Biopôle UL, 9, Avenue de La Forêt de Haye, 54505, Vandoeuvre-Les-Nancy, France.
Université de Lorraine, UMR7365 IMoPA CNRS-UL, Biopôle UL, 9, Avenue de La Forêt de Haye, 54505, Vandoeuvre-Les-Nancy, France.

Mark Helm (M)

Institute of Pharmaceutical and Biomedical Sciences, Johannes Gutenberg-University Mainz, Mainz, Germany.

Pier Paolo Pandolfi (PP)

Molecular Biotechnology Center (MBC), Department of Molecular Biotechnology and Health Sciences, University of Turin, 10126, Turin, TO, Italy.
William N. Pennington Cancer Center, Renown Health, Nevada System of Higher Education, Reno, NV, 89502, USA.

Arkaitz Carracedo (A)

CIC bioGUNE, Basque Research and Technology Alliance (BRTA), Bizkaia Technology Park, 801 Bld, 48160, Derio, Bizkaia, Spain.
Ikerbasque, Basque Foundation for Science, 48011, Bilbao, Spain.
Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain.
Department of Pathology, Basurto University Hospital, 48013, Bilbao, Spain.
Biochemistry and Molecular Biology Department, University of the Basque Country (UPV/EHU), P. O. Box 644, 48080, Bilbao, Spain.

Sandra Blanco (S)

Centro de Investigación del Cáncer and Instituto de Biología Molecular y Celular del Cáncer, Consejo Superior de Investigaciones Científicas (CSIC)-University of Salamanca, 37007, Salamanca, Spain. sandra.blanco@usal.es.
Instituto de Investigación Biomédica de Salamanca (IBSAL), Hospital Universitario de Salamanca, 37007, Salamanca, Spain. sandra.blanco@usal.es.
CIC bioGUNE, Basque Research and Technology Alliance (BRTA), Bizkaia Technology Park, 801 Bld, 48160, Derio, Bizkaia, Spain. sandra.blanco@usal.es.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH